AstraZeneca's new CEO has zeroed in on a site for its new headquarters and R&D center in the U.K. Over the next three years the pharma company ($AZN) plans to build a $500 million complex on an 11-acre site at the Cambridge BioMedical Campus. The new campus will house its U.K. operations for biologics and small molecule research as well as the corporate staff, now operating in London. Report